Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03131726 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 26, 2026 to Jan 26, 2027
    • Study completion date: Mar 30, 2026 to Mar 30, 2028
    • Site contact updated
    • Collaborators expanded, about 2 words
    v8
  2. Primary completion date: Jan 26, 2024 to Jan 26, 2026
    • Study completion date: Mar 30, 2024 to Mar 30, 2026
    • Study title revised
    v7
  3. Primary completion date: Jan 26, 2022 to Jan 26, 2024
    • Study completion date: Mar 30, 2022 to Mar 30, 2024
    v6
  4. Primary completion date: Jan 26, 2020 to Jan 26, 2022
    • Study completion date: Mar 30, 2020 to Mar 30, 2022
    v5
  5. Enrollment target: 115 to 80v4 Show 6 more changesShow less
    • Interventions: Diclofenac Potassium 50 MG (Drug), Simvastatin 40mg (Drug) to Simvastatin 40mg (Drug)
    • Eligibility criteria shortened, about 14 words
    • Secondary endpoints: 6 to 7
    • Study description shortened, about 27 words
    • Study arms: 3 to 2
    • Study title shortened, about 2 words
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Oct 1, 2017 to Jan 26, 2018
    • Study sites: 0 to 1
    • Primary completion date: Oct 1, 2019 to Jan 26, 2020
    • Study completion date: Dec 30, 2019 to Mar 30, 2020
  2. Start date: May 1, 2017 to Oct 1, 2017
    • Primary completion date: May 1, 2019 to Oct 1, 2019
    • Study completion date: Jun 30, 2019 to Dec 30, 2019
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy treated with simvastatin or no treatment.
Trial Details
NCT Number NCT03131726
Lead Sponsor Lund University
Collaborators: Region Skane
Conditions
(from sponsor)		 Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy, Thyroid Associated Orbitopathy
Related terms Graves Ophthalmopathy
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov